Table 1.
Low Risk (LR) and Intermediate Risk (IR) disease
| LR and IR |
Type of study/institution |
Year of study |
Number of patients |
Median FU |
Risk stratification |
Treatment | % on ADT |
Median ADT duration (range) |
Overall bPFS |
ADT benefit for bPFS |
Overall CSS |
ADT benefit for CSS |
Overall OS |
ADT benefit for OS |
Comments and factors predictive of outcome bPFS, CSS and OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LDR | |||||||||||||||
| Ciezki (70) | MultiinstitutionalUS | 1996-2001 | 1668 | 4y | LR:64% IR:36% |
LDR±ADT | 37% | 6 mo | 87.8% | No benefit | NR | NR | NR | NR | NR |
| Potters (71) | New York Institutions US | 1992-2000 | 1449 | 6.8y | NR | LDR±EBRT±ADT | 27% | 5.2 mo (1-24) | 77% | No benefit | 93% | NR | 81% | NR | bPFS (GS, iPSA, D90) |
| Ohashi (72) | Multiinstitutional Japan | 2003-2009 | 663 | 5y | LR: 67% fIR: 33% |
LDR±ADT | 44% | 3 mo | 95.9% | No benefit | 99% | NR | 96% | NR | bPFs (D90, risk group) |
| Morris (73) | British Columbia, Canada | 1998-2003 | 1006 | 7.5y | LR: 58% fIR: 42% |
LDR±ADT | 65% | 6 mo | 95% | No benefit | 99% | NR | 83% | No benefit | bPFS (log iPSA, D90 in ADT naïve) OS (Age, log iPSA) |
| Martin (74) | Quebec City Canada | 1994-2001 | 396 | 5y | LR: 69% fIR: 31% |
LDR±ADT | 65% | 6mo | 88.5% | No benefit | NR | NR | NR | NR | bPFS (GS and stage) |